Celcuity Balance Sheet Health
Financial Health criteria checks 4/6
Celcuity has a total shareholder equity of $53.5M and total debt of $323.4M, which brings its debt-to-equity ratio to 604.3%. Its total assets and total liabilities are $410.2M and $356.6M respectively.
Key information
604.26%
Debt to equity ratio
US$323.43m
Debt
| Interest coverage ratio | n/a |
| Cash | US$387.06m |
| Equity | US$53.53m |
| Total liabilities | US$356.64m |
| Total assets | US$410.16m |
Recent financial health updates
Recent updates
Priority FDA Review And Phase III Data Will Transform This Oncology Pure Play
Catalysts About Celcuity Celcuity is a clinical stage oncology company focused on developing gedatolisib, a targeted therapy for advanced breast and prostate cancers. What are the underlying business or industry changes driving this perspective?
Single Drug Dependence And Heavy Financing Will Shape A Challenging Future
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?
Future Oncology Approvals And Pipeline Expansion Will Support A Stable Long Term Outlook
Catalysts About Celcuity Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer. What are the underlying business or industry changes driving this perspective?Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond
Summary Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones. I maintain a long-term Buy rating on CELC, anticipating further upside as pivotal data, regulatory filings, and potential M&A activity unfold through 2027–2028. Read the full article on Seeking AlphaCelcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Summary Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 trials. Gedatolisib shows promising efficacy and safety, especially in combination therapies for advanced breast cancer, with significant ORR and mPFS improvements. Financially, Celcuity has a strong cash position and secured funding, ensuring a runway through 2026, despite patent expiration risks. Despite Stifel's buy rating and blockbuster potential, the risk-reward profile of CELC remains unattractive at this stage. Read the full article on Seeking AlphaCelcuity: Flying A Phase 3 Trial Right Under Your Nose
Summary Celcuity Inc. is a cancer-focused biotech company with one pipeline candidate, gedatolisib, showing promise in breast and prostate cancer. Gedatolisib is a differentiated PI3K inhibitor with a favorable tolerability profile, but faces risks associated with the history of PI3K inhibition in cancer medicine. CELC has a strong cash position to fund key data-related catalysts, but the jump from phase 1 to phase 3 trials carries inherent risks. Read the full article on Seeking AlphaCelcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Shares of micro-cap company Celcuity (NASDAQ:CELC) added 12.7% to $10.42 after hours on Monday as the clinical stage biotech was granted a Breakthrough Therapy designation by the U.S. FDA for its breast cancer treatment gedatolisib. The U.S. drug regulator granted gedatolisib the designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during treatment with a CDK4/6 therapy and a non-steroidal aromatase inhibitor. The FDA's Breakthrough Therapy designation process is meant to expedite the review of drugs that are intended for the treatment of serious diseases. CELC's gedatolisib had previously received a FDA Fast Track designation in Jan.Celcuity: Nipping The Oncogenic Bud
Celcuity analyzes live tumor cells for oncogenic pathways. It identifies abnormal oncogenic signaling pathways to detect new treatment options. The company develops targeted therapies for cancer patients.Financial Position Analysis
Short Term Liabilities: CELC's short term assets ($408.9M) exceed its short term liabilities ($33.2M).
Long Term Liabilities: CELC's short term assets ($408.9M) exceed its long term liabilities ($323.4M).
Debt to Equity History and Analysis
Debt Level: CELC has more cash than its total debt.
Reducing Debt: CELC's debt to equity ratio has increased from 0% to 604.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CELC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CELC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/20 21:09 |
| End of Day Share Price | 2026/05/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celcuity Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arlinda Lee | Canaccord Genuity |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Alexander Nowak | Craig-Hallum Capital Group LLC |